Literature DB >> 34130290

Age-Related Macular Degeneration: Pathophysiology, Management, and Future Perspectives.

Rita Flores1,2, Ângela Carneiro3, Miguel Vieira1, Sandra Tenreiro2, Miguel C Seabra2,4.   

Abstract

Among older adults, age-related macular degeneration (AMD) is a prevalent disabling condition that begins as subtle visual disturbances and can progress to permanent loss of central vision. In its late neovascular form, AMD is treatable with inhibitors of vascular endothelial growth factor, the key driver of exudative disease. In the atrophic form, treatment remains elusive. This review addresses the natural history of AMD - through early, intermediate, and advanced disease stages - and concentrates on diagnosis and risk stratification, deficiencies of current treatments, and the promising findings of emerging therapies.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Age-related macular degeneration; Biomarkers; Geographic atrophy; Macular neovascularization

Mesh:

Substances:

Year:  2021        PMID: 34130290     DOI: 10.1159/000517520

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  7 in total

1.  Protective Effects of Gamma-mangostin on Hydrogen Peroxideinduced Cytotoxicity in Human Retinal Pigment Epithelial Cells.

Authors:  Pei-Shin Hu; Ning-Yi Hsia; Wei-Ching Chien; Mei-Chin Mong; Te-Chun Hsia; Heng-Ming Chang; Yun-Chi Wang; Wen-Shin Chang; DA-Tian Bau; Chia-Wen Tsai
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

Review 2.  More than Meets the Eye: The Aryl Hydrocarbon Receptor is an Environmental Sensor, Physiological Regulator and a Therapeutic Target in Ocular Disease.

Authors:  Christine L Hammond; Elisa Roztocil; Vardaan Gupta; Steven E Feldon; Collynn F Woeller
Journal:  Front Toxicol       Date:  2022-03-03

3.  WAMD: From Pathophysiology to Therapeutic Treatments.

Authors:  Feliciana Menna; Alessandro Meduri; Stefano Lupo; Enzo Maria Vingolo
Journal:  Biomedicines       Date:  2022-08-17

4.  Long-Term Consequences of COVID-19 Lockdown in Neovascular AMD Patients in Spain: Structural and Functional Outcomes after 1 Year of Standard Follow-Up and Treatment.

Authors:  Daniela Rego-Lorca; Alicia Valverde-Megías; José Ignacio Fernández-Vigo; Carlos Oribio-Quinto; Antonio Murciano-Cespedosa; Julia Sánchez-Quirós; Juan Donate-López; Julián García-Feijóo
Journal:  J Clin Med       Date:  2022-08-28       Impact factor: 4.964

Review 5.  Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.

Authors:  Sławomir Liberski; Małgorzata Wichrowska; Jarosław Kocięcki
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

Review 6.  Ranibizumab port delivery system: a clinical perspective.

Authors:  David A Eichenbaum; Abrahim Ahmed; Farhan Hiya
Journal:  BMJ Open Ophthalmol       Date:  2022-09

Review 7.  Advances in the therapeutic application and pharmacological properties of kinsenoside against inflammation and oxidative stress-induced disorders.

Authors:  Li Lu; Yuan Xiong; Ze Lin; Xiangyu Chu; Adriana C Panayi; Yiqiang Hu; Juan Zhou; Bobin Mi; Guohui Liu
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.